CONTACT:Chad RubinThe Trout Groupcrubin@troutgroup.com(646) 378-2947orLee SternThe Trout Grouplstern@troutgroup.com(646) 378-2922
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the Ladenburg Thalmann 2016 Healthcare Conference at Sofitel Hotel in New York City, NY on Tuesday, September 27, 2016, at 11:30am Eastern time. The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: http://wsw.com/webcast/ladenburg2/vcel. About Vericel Corporation Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel ® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel ® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI ® is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com. Epicel ®, Carticel ® and MACI ® are registered trademarks of Vericel Corporation. ©2016 Vericel Corporation. All rights reserved.